ArticleCancer medicine2026
FCGBP Promotes Glioma Growth by Regulating JAK2/STAT3/c-Myc Pathway.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- FCGBP Promotes Glioma Growth by Regulating JAK2/STAT3/c-Myc Pathway.Cancer medicine · 2026Article
- Integrated network toxicology, bioinformatics, and molecular docking reveal the potential molecular mechanisms linking bisphenol A to glioma progression.Frontiers in bioinformatics · 2026Article
- FCGBP promotes malignant phenotypes of glioblastoma cells via activation of the TGF-β1 signaling pathway.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFCGBP has been implicated in the development of a variety of tumors, but its exact role in glioma progression remains unclear.
methodsThis study utilized qRT-PCR, Western blotting (WB), immunohistochemistry (IHC), and other techniques to assess FCGBP expression in glioma tissues. Additionally, various functional experiments were conducted to investigate its role in glioma progression. Animal models were employed to further elucidate the function of FCGBP, with a particular focus on its impact on the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) signaling pathway.
resultsThe research findings indicated that FCGBP is significantly overexpressed in glioma and is closely associated with higher tumor grades and unfavorable clinical outcomes. Functional assays demonstrated that FCGBP promotes glioma cell aggressiveness by activating the JAK2/STAT3 signaling pathway.
conclusionThis study highlights the critical role of FCGBP in glioma aggression and poor prognosis, indicating that it could serve as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.